The most high yeild connection between beta-2 antagonists and the pancreas/insulin is probably that:
Non-specific (B1/B2) Antagonists, like propranolol, should not be used in diabetic patients, as they mask the early adrenergic side effects of HYPOglycemia. Hypoglycemia triggers catechols which cause tachycardia, diaphoresis, anxiety, etc. early on. This can be very dangerous in these patients, if these symptoms are masked.
This seems like the most logical clinical scenario that would come up on the boards. I just can't see them asking flat out, "Do Beta-antagonists increase or decrease insulin release in the pancreas?" Try and think of "how" they would ask the question. Figure out "why" its important clinically.
And, another thing. Remeber that although Beta-2 adrenergic Agonists can cause insulin release from the pancreas, they also stimulate Glycogenolysis in the liver, which can lead to hyperglycemia. At least, this is what i can remember on the subject. I think these would be more of the systemic Beta-2 agonists, like PO Albuterol and Clenbuterol and not the aerosolized kind used in acute asthma management. Typically not going to see hyperglycemia in an asthmatic, unless they are on PO steroids or they just took 15 puffs of their inhaler.